Orion Corporation
Clinical trials sponsored by Orion Corporation, explained in plain language.
Orion is a Finnish pharmaceutical company developing and marketing drugs, including for CNS and respiratory diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new pill outsmart resistant prostate cancer? Results expected Oct 2026 (estimated)
-
Can a new pill shrink advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for advanced cancers: first human trial of ODM-212 begins
Disease control Recruiting nowThis study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ODM-212 combined with other cancer treatments in people with advanced solid tumors, including mesothelioma, pancreatic cancer, and non-small cell lung cancer. The trial has two parts: first finding a safe dose, then checking how well it works. A…
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC